Learnings from Clinical Development with MH002 in IBD and Translation to LBP Development for Parkinson’s Disease
Time: 1:30 pm
day: Conference Day Two, Track Two, PM
Details:
- Reviewing Phase 2 clinical data of MH002, a next-generation microbiome therapy utilizing MRM Health’s CORAL® Technology, combining six commensal strains for targeted action in Ulcerative Colitis (UC) and Pouchitis
- Lessons learned and highlights on its ability to restore gut microbiome balance and improve clinical outcomes
- Translation of knowhow from clinical program to develop LBPs for Parkinson’s Disease; update on preclinical data
